UY25308A1 - Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona. - Google Patents

Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona.

Info

Publication number
UY25308A1
UY25308A1 UY25308A UY25308A UY25308A1 UY 25308 A1 UY25308 A1 UY 25308A1 UY 25308 A UY25308 A UY 25308A UY 25308 A UY25308 A UY 25308A UY 25308 A1 UY25308 A1 UY 25308A1
Authority
UY
Uruguay
Prior art keywords
hydrate
provides
thiazolidine
dione
pyridyl
Prior art date
Application number
UY25308A
Other languages
English (en)
Inventor
Blackier
Lee
Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY25308A1 publication Critical patent/UY25308A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un proceso para preparar un hidrato de la sal de ácido maleico de 5-[4-[2-(N-metil-N-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona, cuyo hidrato: a- comprende agua en el intervalo de 0,4 a 2,5% p/p; y b- proporciona un espectro infrarrojo que contiene picos a 1749, 1703, 1645, 1623, 1365, y 736cm-1; y/o c- proporciona un modelo de difracción de rayos X en polvo (XRPD) sustancialmente como se presenta en la figura ll y/o d- proporciona un espectro Raman que contiene picos a 3106, 3069, 3002, 1750, 1718, etc; y/o e- proporciona un espectro de resonancia magnetica nuclear un estado sólido que contiene desplazamientos químicos sustancialmente, caracterizados por que el proceso comprende cristalizar la sal de ácido maleico de 5-[4-[2-(N-metil-N-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona en etanol que contiene de 15 a 25% en volumen de agua. Este hidrato tiene propiedades farmacéuticas útiles y se indica en particular que es útil para el tratamiento y/o la profilaxis de diabetes mellitus y ciertas complicaciones de la misma.
UY25308A 1997-12-16 1998-12-15 Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona. UY25308A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726566.4A GB9726566D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical
UY25304A UY25304A1 (es) 1997-12-16 1998-12-15 Forma hidratada de maleato de rosiglitazona

Publications (1)

Publication Number Publication Date
UY25308A1 true UY25308A1 (es) 1999-07-19

Family

ID=10823692

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25304A UY25304A1 (es) 1997-12-16 1998-12-15 Forma hidratada de maleato de rosiglitazona
UY25308A UY25308A1 (es) 1997-12-16 1998-12-15 Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY25304A UY25304A1 (es) 1997-12-16 1998-12-15 Forma hidratada de maleato de rosiglitazona

Country Status (35)

Country Link
EP (2) EP1661895A1 (es)
JP (1) JP2002508373A (es)
KR (1) KR100549142B1 (es)
CN (3) CN1281453A (es)
AP (1) AP1365A (es)
AR (1) AR017214A1 (es)
AU (1) AU1967999A (es)
BG (1) BG64988B1 (es)
BR (1) BR9813600A (es)
CA (1) CA2314107A1 (es)
CO (1) CO4980880A1 (es)
CZ (1) CZ299965B6 (es)
DZ (1) DZ2681A1 (es)
EA (1) EA004260B1 (es)
EG (1) EG22337A (es)
GB (1) GB9726566D0 (es)
HR (1) HRP20000408B1 (es)
HU (1) HUP0100509A3 (es)
IL (1) IL136424A (es)
IN (1) IN192487B (es)
MA (1) MA26580A1 (es)
MY (1) MY135612A (es)
NO (1) NO317254B1 (es)
OA (1) OA11766A (es)
PE (1) PE20000058A1 (es)
PL (1) PL341146A1 (es)
RS (1) RS50126B (es)
SA (1) SA99191115B1 (es)
SK (1) SK286618B6 (es)
TR (2) TR200001799T2 (es)
TW (1) TW509690B (es)
UA (1) UA72198C2 (es)
UY (2) UY25304A1 (es)
WO (1) WO1999031095A1 (es)
ZA (1) ZA9811506B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
HUP0200929A3 (en) * 1999-04-23 2004-03-29 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
CO5170419A1 (es) * 1999-04-23 2002-06-27 Smithkline Beecham Plc Nuevo compuesto antidiabetico con base en sales del acido maleico
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
EA004244B1 (ru) * 2000-04-25 2004-02-26 Киорин Фармасьютикал Ко., Лтд. Новый стабильный кристалл производного тиазолидиндиона и способ его получения
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
JP2004509961A (ja) * 2000-09-26 2004-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 5−[4−[2−[n−メチル−n−(2−ピリジル)アミノ]エトキシ]ベンジル]チアゾリジン−2,4−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases

Also Published As

Publication number Publication date
IL136424A0 (en) 2001-06-14
CO4980880A1 (es) 2000-11-27
SK9172000A3 (en) 2001-01-18
DZ2681A1 (fr) 2004-06-20
CN1281453A (zh) 2001-01-24
AP1365A (en) 2005-01-26
HUP0100509A2 (hu) 2002-05-29
BG104603A (en) 2001-03-30
IN192487B (es) 2004-04-24
AU1967999A (en) 1999-07-05
CN101381367A (zh) 2009-03-11
ZA9811506B (en) 2000-11-06
NO20003069L (no) 2000-06-15
EP1661895A1 (en) 2006-05-31
RS50126B (sr) 2009-03-25
AR017214A1 (es) 2001-08-22
EG22337A (en) 2002-12-31
NO317254B1 (no) 2004-09-27
CZ20002204A3 (cs) 2000-11-15
UY25304A1 (es) 2000-12-29
EA200000654A1 (ru) 2000-12-25
CN101302215A (zh) 2008-11-12
AP2000001831A0 (en) 2000-06-30
PL341146A1 (en) 2001-03-26
TW509690B (en) 2002-11-11
GB9726566D0 (en) 1998-02-11
HRP20000408A2 (en) 2000-08-31
JP2002508373A (ja) 2002-03-19
BG64988B1 (bg) 2006-11-30
HUP0100509A3 (en) 2002-06-28
BR9813600A (pt) 2000-10-10
KR20010033141A (ko) 2001-04-25
WO1999031095A1 (en) 1999-06-24
UA72198C2 (en) 2005-02-15
CZ299965B6 (cs) 2009-01-07
TR199802625A2 (xx) 1999-10-21
IL136424A (en) 2003-12-10
NO20003069D0 (no) 2000-06-15
YU36300A (sh) 2004-03-12
TR199802625A3 (tr) 1999-10-21
EP1040110A1 (en) 2000-10-04
TR200001799T2 (tr) 2001-01-22
OA11766A (en) 2005-07-19
SK286618B6 (sk) 2009-02-05
SA99191115B1 (ar) 2006-10-11
EA004260B1 (ru) 2004-02-26
PE20000058A1 (es) 2000-02-26
CA2314107A1 (en) 1999-06-24
MY135612A (en) 2008-05-30
KR100549142B1 (ko) 2006-02-03
MA26580A1 (fr) 2004-12-20
HRP20000408B1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
UY25308A1 (es) Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona.
UY25309A1 (es) Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona
NZ515163A (en) Thiazolidinedione derivative and its use as antidiabetic
UY26121A1 (es) Nuevo compuesto farmacéutico
CO4990927A1 (es) Nuevo producto farmaceutico -n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
AP1607A (en) Thiazolidinedione derivative and its use as antidiabetic.
UY26113A1 (es) Forma polimórfica de sal del ácido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
WO2000063205A3 (en) Thiazolidinedione derivative and its use as antidiabetic
ECSP003436A (es) Nuevos compuestos
ECSP003438A (es) Nuevos compuestos
ECSP003437A (es) Nuevos compuestos
ECSP982779A (es) Un hidrato de la sal de acido maleico, proceso para la preparacion, composicion farmaceutica y su uso en medicina
TH84544A (th) ไฮเดรทชนิดใหม่

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20181215